Biomedical research at Oslo University Hospital

Publications (original articles or review articles) published in 2020 from OUS - Section for Preventive Cardiology

10 publications found

Bergmark BA, O'Donoghue ML, Murphy SA, Kuder JF, Ezhov MV, Ceška R, Gouni-Berthold I, Jensen HK, Tokgozoglu SL, Mach F, Huber K, Gaciong Z, Lewis BS, Schiele F, Jukema JW, Pedersen TR, Giugliano RP, Sabatine MS (2020)
An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial
JAMA Cardiol, 5 (6), 709-713
DOI 10.1001/jamacardio.2020.0728, PubMed 32347887

Deedwania P, Murphy SA, Scheen A, Badariene J, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR, Sabatine MS, Giugliano RP (2020)
Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial
JAMA Cardiol (in press)
DOI 10.1001/jamacardio.2020.3151, PubMed 32785614

Gencer B, Mach F, Guo J, Im K, Ruzza A, Wang H, Kurtz CE, Pedersen TR, Keech AC, Ott BR, Sabatine MS, Giugliano RP, FOURIER Investigators (2020)
Cognition After Lowering LDL-Cholesterol With Evolocumab
J Am Coll Cardiol, 75 (18), 2283-2293
DOI 10.1016/j.jacc.2020.03.039, PubMed 32381158

Gencer B, Mach F, Murphy SA, De Ferrari GM, Huber K, Lewis BS, Ferreira J, Kurtz CE, Wang H, Honarpour N, Keech AC, Sever PS, Pedersen TR, Sabatine MS, Giugliano RP (2020)
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial
JAMA Cardiol, 5 (8), 952-957
DOI 10.1001/jamacardio.2020.0882, PubMed 32432684

Johansen N, Tonstad S, Liavaag AH, Selmer RM, Tanbo TG, Michelsen TM (2020)
Risk of cardiovascular disease after preventive salpingo-oophorectomy
Int J Gynecol Cancer, 30 (5), 575-582
DOI 10.1136/ijgc-2019-000856, PubMed 32332121

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O, ESC Scientific Document Group (2020)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
Eur Heart J, 41 (1), 111-188
DOI 10.1093/eurheartj/ehz455, PubMed 31504418

Marston NA, Gurmu Y, Melloni GEM, Bonaca M, Gencer B, Sever PS, Pedersen TR, Keech AC, Roselli C, Lubitz SA, Ellinor PT, O'Donoghue ML, Giugliano RP, Ruff CT, Sabatine MS (2020)
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism
Circulation, 141 (20), 1600-1607
DOI 10.1161/CIRCULATIONAHA.120.046397, PubMed 32223429

Rabanal KS, Igland J, Tell GS, Jenum AK, Klemsdal TO, Ariansen I, Meyer HE, Selmer RM (2020)
Validation of the cardiovascular risk model NORRISK 2 in South Asians and people with diabetes
Scand Cardiovasc J, 1-7 (in press)
DOI 10.1080/14017431.2020.1821909, PubMed 33073627

Tonstad S, Arons C, Rollema H, Berlin I, Hajek P, Fagerström K, Els C, McRae T, Russ C (2020)
Varenicline: mode of action, efficacy, safety and accumulated experience salient for clinical populations
Curr Med Res Opin, 36 (5), 713-730
DOI 10.1080/03007995.2020.1729708, PubMed 32050807

Wiviott SD, Giugliano RP, Morrow DA, De Ferrari GM, Lewis BS, Huber K, Kuder JF, Murphy SA, Forni DM, Kurtz CE, Honarpour N, Keech AC, Sever PS, Pedersen TR, Sabatine MS (2020)
Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial
JAMA Cardiol, 5 (7), 787-793
DOI 10.1001/jamacardio.2020.0764, PubMed 32347885